Inclusion Criteria:

          -  Adequate liver, kidney and hematology function as demonstrated by laboratory values
             detailed in the study protocol.

          -  An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

        Dose-Escalation:

          -  Arm A: Participants with an advanced solid tumor who have progressed on standard
             therapies known to provide clinical benefit and/or participants who have refused or
             are intolerant of such therapy.

          -  Arm B (non-small-cell-lung-cancer [NSCLC]): Participants with histologically or
             cytologically confirmed NSCLC who previously progressed during or after an
             anti-programmed cell death (PD)-1 or PD ligand 1 (PD-L1) therapy and a platinum-based
             regimen in the recurrent or metastatic setting.

        Dose-Expansion:

          -  Arm 1, 2, and 3 (triple-negative breast cancer [TNBC]): Participants with
             histologically or cytologically confirmed breast adenocarcinoma that is estrogen
             receptor/progesterone receptor/human epidermal growth factor receptor (HER)2-negative
             who must have disease progression during or after at least 1 systemic therapy that
             included a taxane in the metastatic or recurrent setting and who are treatment-naïve
             to immunotherapy.

          -  Arm 4 (TNBC): Participants with histologically or cytologically confirmed TNBC who
             have received no previous anti-cancer therapy for TNBC, and who are PD-L1 negative on
             tumor tissue by immunohistochemistry (IHC) assay.

          -  Arm 5 (NSCLC): Participants with histologically or cytologically confirmed NSCLC who
             previously progressed either during or after an anti-PD-1 or PD-L1 therapy and a
             platinum-based regimen in the recurrent or metastatic setting.

        Exclusion Criteria:

          -  Has history of inflammatory bowel disease or pneumonitis.

          -  Has uncontrolled metastases to the central nervous system.

          -  Has a concurrent malignancy that is clinically significant, treatment is required, or
             the participant is not clinically stable.

          -  Has had a major surgery ≤ 28 days prior to the first dose of study drug or the
             surgical wound is not fully healed.

          -  Has previously treated with an anti-PD- or PD-L1-targeting agent and had during the
             course of their therapy:

          -  any immune-mediated toxicity of Grade 3 or worse severity

          -  treatment of the toxicity with systemic corticosteroids

          -  any hypersensitivity to the PD-1 or PD-L1-targeting agent

          -  any treatment-related toxicity resulting in discontinuation of the PD-1 or PD-L1
             targeting agent